AzTrials
AzTrials

Growth DisordersNCT05242224

Evolutionary Nutrition Pilot: Enhancing Fetal Growth and Brain Development

A study testing Evolutionary Nutrition Package in people with Growth Disorders and Malnutrition, Fetal, run by Washington University School of Medicine at 1 site in Ecuador.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Globally, 250 million children do not reach their developmental potential and 155 million are stunted, yet few population-based studies have examined the direct effects of nutrient deficiencies on early brain development. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Growth Disorders, Malnutrition, Fetal, Stunting
What is being tested?
Evolutionary Nutrition Package
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteEcuador
Study dates
5 Jan 2022to Jun 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • healthy
  • in their first trimester
  • carrying a singleton pregnancy

Who cannot join

  • less than 18 years of age
  • have a chronic health condition (HIV, TB, epilepsy, etc.)
  • have a multiple pregnancy (twins, triplets, etc.)
  • intend to move away from the study area
  • have known allergies to eggs or fish
  • have a blood pressure greater than 160/100

Trial locations and contacts

1 site in 1 country.

Ecuador1 site
  • Universidad San Francisco de Quito

    Quito, Pichincha, 170901

Other trials in Ecuador

About this study

Globally, 250 million children do not reach their developmental potential and 155 million are stunted, yet few population-based studies have examined the direct effects of nutrient deficiencies on early brain development. This study will examine an evolutionary nutrition intervention during pregnancy derived from diets consumed for 99.9% of hominin history when bodies and brains were healthier. A pilot clinical trial will be conducted in the central highlands of Ecuador to compare fetal and newborn outcomes among women randomized to: 1) evolutionary nutrition package (high quality diet plus nutrition messaging); and 2) control (standard-of care supplements). Ultrasound brain measures, nutrition and morbidity data, and blood metabolomics will be assessed at 21 weeks gestational age, 37 weeks gestational stage, and postpartum. This pilot study uniquely combines the expertise of multiple disciplines - public health nutrition, radiology, neuroscience, and metabolomics - to examine the potential for improved nutrition on early growth and brain development with vital public health implications.

Read the detailed description

The pilot trial will be conducted in the highlands of Ecuador in a mixed indigenous and non-indigenous population of pregnant women. Nationally, the stunting prevalence among young children is 25.3%, but large disparities within the country especially indigenous communities where stunting prevalence is nearly double, 42.3% (Freire et al., 2014). Incidence of low birthweight (8%) also varies by population in Ecuador, and may represent in utero growth restriction (IUGR) and other harmful exposures during pregnany (UNICEF 2012). While a large proportion of women have at least one antenatal care visit (84%), Only 58% of women in Ecuador meet the the WHO recommended 4+ antenatal care visits. This pilot project will leverage learnings from the Lulun Project and a previous antenatal health study (Gallegos et al. 2017) to design a social marketing campaign that encourages participation and high compliance. For this pilot RCT, the investigators will recruit pregnant women accessing antenatal care from Centro de Salud El Quinche in Pichincha province. Our target population will include those from poor households in particular (who access free public health services) with higher risks for IUGR and undernutrition during pregnancy.

The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes. In order to adapt the food groups to the Ecuador context, the investgators first developed a list of foods appropriate for the Ecuador context within each food group (Table 1). The food list draws on evidence from the Ministry of Health in Ecuador and USFQ for commonly consumed foods, notably among indigneous populations (Gallegos et al. 2010). Criteria for the full list of foods were the following: culturally appropriate; economically affordable and accessible; and environmentally sustainable. As was the experience with eggs in the Lulun Project, application of these criteria better ensure translation of findings within communities in the future.

Pregnant women will be recruited during first trimester of pregnancy and randomized to intervention group (EN plate + nutrition messaging + standard of care supplements) or control group (standard of care supplements). The intervention period will occur during second and third trimesters. Food supplies sufficient for one EN plate per day for 7 days will be delivered to pregnant women on a weekly basis. Under the supervision of the nutrition-trained field director, foods from each food group in pre-specified nutrient proportions will be secured from local food producers. Consideration will be given to including foods that do not require refrigeration over a one-week period. Careful documentation will be made of the foods contained in the weekly box in order to calculate exact quantity of nutrients provided. Due to concerns about food sharing that were evident in our qualitative research findings, additional food supplies will be provided for other household members in a separate container. Suggested menus and recipes will be provided with each delivery depending on the included foods.

Nutrition messages, developed in tandem with the social marketing campaign described below, will emphasize the importance of the food provisions for the participating pregnant women, but communicate the value of the EN plate for all household members. Messaging each week will reinforce the importance of eliminating ultraprocessed foods from the diet and reducing rice consumption. The absence of ultra processed foods is integral to our hypothesized effect and critical for confronting the dual burden of over- and under-nutrition in Ecuador (Freire et al. 2014). During each weekly food delivery visit, data will be collected on adherence and morbidities.

Being tested
Evolutionary Nutrition Package
Medical subject headings
Growth Disorders, Fetal Nutrition Disorders, Malnutrition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Evolutionary Nutrition PackageOther

    The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.

Study groups in NCT05242224
Study groupRoleWhat they receive
Experimental GroupExperimentalReceives evolutionary nutrition package [high quality diet plus nutrition messaging + standard of care (iron-folic acid and calcium supplements)]
Receives: Other: Evolutionary Nutrition Package
Control GroupNo interventionReceives standard-of-care, iron-folic acid and calcium supplements.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Length-for-age Z (LAZ)

    LAZ is a measure of stunting, whether a child is the appropriate length/height for their age

    Measured: 6 months

  2. Plasma concentrations of Docosahexaenoic acid (DHA)

    Plasma concentration of DHA measured in µg/mL

    Measured: 6 months

  3. Plasma concentrations of Linoleic acid (LA)

    Plasma concentration of LA measured in µg/mL

    Measured: 6 months

  4. Plasma concentrations of α-Linoleic acid (ALA)

    Plasma concentration of ALA measured in µg/mL

    Measured: 6 months

  5. Plasma concentrations of Betaine

    Plasma concentration of Betaine measured in µg/mL

    Measured: 6 months

  6. Plasma concentrations of Methionine

    Plasma concentration of Methionine measured in µg/mL

    Measured: 6 months

  7. Plasma Concentration of Choline

    Plasma concentration of Choline measured in µg/mL

    Measured: 6 months

  8. Plasma Concentration of Iron (Fe)

    Plasma concentration of Iron (Fe) measured in mg/mL

    Measured: 6 months

  9. Plasma Concentration of Zinc (Zn)

    Plasma concentration of Zinc (Zn) measured in mg/mL

    Measured: 6 months

  10. Plasma Concentration of Selenium (Se)

    Plasma concentration of Selenium (Se) measured in mg/mL

    Measured: 6 months

  11. Brain structure development--Gangliothalamic ovoid (GTO) volume

    GTO volume measured in cm3

    Measured: 4 months

  12. Brain structure development--Gangliothalamic ovoid (GTO) diameter

    GTO diameter measured in cm

    Measured: 4 months

  13. Brain structure development--Gangliothalamic ovoid (GTO) craniocaudal

    GTO craniocaudal measured in cm

    Measured: 4 months

  14. Brain structure development-- thalamic diameter

    Thalamic diameter in cm

    Measured: 4 months

Secondary outcomes (1)
  1. Maternal Morbidity

    Rate of morbidities common during pregnancy including anemia, urinary tract infections, hypertension, gestational diabetes, respiratory infections, and hyperemesis gravidarum.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Feb 2022
  2. Study start5 Jan 2022
  3. Primary completion1 Aug 2024
  4. Study completionJun 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05242224
Sponsor's protocol ID
2019-044E
Status last verified
Oct 2024
First submitted
28 Jun 2019
Last updated
28 Oct 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Evolutionary Nutrition Package in people with Growth Disorders and Malnutrition, Fetal, run by Washington University School of Medicine at 1 site in Ecuador.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 28 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Ecuador. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Length-for-age Z (LAZ) (time frame: 6 months). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in